You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PNAS this week: effect of premature termination codons in the DMD gene, knock-down of DUX4 in facioscapulohumeral muscular dystrophy, and more.
The project will provide approved researchers with access to samples and deidentified data collected from volunteer patients with Duchenne muscular dystrophy.
Hallmarks of the genetic disease, which can result in life-threatening cardiac complications, include progressive weakness and loss of heart muscle.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.
The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.
In PNAS this week: DNA vaccine-based approach for Duchenne muscular dystrophy tested in mice, antimicrobial found in bear saliva, and more.
Stat News reports federal regulators have halted Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy trial.
The effort, sponsored by two therapeutics companies, is providing no-cost genetic testing and counseling for people with Duchenne who otherwise couldn't afford it.
In Science this week: gene variant linked to inflammatory bowel disease, and more.
The researchers found that it's not necessary to design individual guide RNAs for each DMD mutation or excise large genomic regions with pairs of guide RNAs.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.